


PHARMACEUTICAL 2021

Equillium Inc. Rank 179 of 409





PHARMACEUTICAL 2021

Equillium Inc. Rank 179 of 409

The relative strengths and weaknesses of Equillium Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Equillium Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 226% points. The greatest weakness of Equillium Inc. is the variable Net Income, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is -89%, being 266% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	85,174
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,245
Liabilities, Non-Current	54
Other Assets	15
Other Compr. Net Income	-318
Other Expenses	0
Other Liabilities	8,275
Other Net Income	-265
Property and Equipment	239
Research and Development	19,384
Revenues	0
Selling, General and Administrative Expense	10,164

Output Variable	Value in 1000 USD
Assets	85,428
Liabilities	15,574
Expenses	29,548
Stockholders Equity	69,854
Net Income	-29,813
Comprehensive Net Income	-29,972
Economic Capital Ratio	-89%